Skip to main content

Advertisement

Log in

Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis

  • Original Paper
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

Abstract

Background

Amyloid light chain (AL) amyloidosis is a rare disease with poor prognosis and limited therapeutic alternatives. Recently, one clinical case with cardiac involvement, as well as a compelling evidence of green tea polyphenol, epigallocatechin-3-gallate (EGCG), inducing the formation of benign aggregation products that do not polymerize into fibrils were published. This is a report of the cardiac effects of green tea consumption in these patients.

Methods

Patients with known cardiac involvement in AL amyloidosis were examined by routine cardiovascular examinations that took place every 3–6 months. Of 59 patients with cardiac involvement, 11 revealed a decrease of at least 2 mm of interventricular wall thickness, after initiation of regular green tea consumption (GT). A matched historic control group (n = 22) was selected. Comprehensive echocardiography was conducted at every control examination and analyzed offline by two independent examiners.

Results

GT patients showed an improvement in New York Heart Association (NYHA) class from a median of 3 (25th, 75th percentiles: 2, 3) to 2 (2, 3), P = 0.038. Septal thickness decreased from 18 (18, 20) to 16 (16, 17) mm, P = 0.021. Left ventricular mass index decreased from 175 (154, 180) to 133 (128, 154) g/m2, P = 0.007. Comparing both groups, an increase in left ventricular ejection fraction could be found in the GT group, 65 (51, 73) versus 53 (47, 59)%, P = 0.012. These changes could not be observed in the control group.

Conclusion

Consumption of green tea polyphenol EGCG in patients with cardiac involvement with AL amyloidosis causes a significant decrease in left ventricular wall thickness and mass, as well as an improvement in NYHA functional classification and left ventricular ejection fraction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Gertz MA, Comenzo R, Falk RH et al (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol 79:319–328

    Article  PubMed  Google Scholar 

  2. Gertz MA, Lacy MG, Dispenzieri A (2004) Therapy for immunoglobulin light chain amyloidosis: the new and the old. Blood Rev 18:17–37

    Article  PubMed  Google Scholar 

  3. Roig E, Almenar L, González-Vílchez F et al (2009) Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the Spanish registry for heart transplantation. Am J Transplant 9:1414–1419

    Article  CAS  PubMed  Google Scholar 

  4. Hunstein W (2007) Epigallocatechin-3-gallate in AL amyloidosis: a new therapeutic option? Blood 110:2216

    Article  CAS  PubMed  Google Scholar 

  5. Shammas MA, Neri P, Koley H et al (2006) Specific killing of multiple myeloma cells by (−)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood 108:2804–2810

    Article  CAS  PubMed  Google Scholar 

  6. Shanafelt TD, Lee YK, Call TG et al (2006) Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies. Leuk Res 30:707–712

    Article  CAS  PubMed  Google Scholar 

  7. Shanafelt TD, Call TG, Zent CS et al (2009) Phase I trial of daily oral polyphenon E in patients with asymptomatic Rai Stage 0 to II chronic lymphocytic leukemia. J Clin Oncol 27:3808–3814

    Article  CAS  PubMed  Google Scholar 

  8. Rezai-Zadeh K, Shytle D, Sun N et al (2005) Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci 25:8807–8814

    Article  CAS  PubMed  Google Scholar 

  9. Lorenz M, Hellige N, Rieder P et al (2008) Positive inotropic effects of epigallocatechin-3-gallate (EGCG) involve activation of Na+/H+ and Na+/Ca2 + exchangers. Eur J Heart Fail 10:439–445

    Article  CAS  PubMed  Google Scholar 

  10. Hao J, Kim CH, Ha TS, Ahn HY (2007) Epigallocatechin-3 gallate prevents cardiac hypertrophy induced by pressure overload in rats. J Vet Sci 8:121–129

    Article  PubMed  Google Scholar 

  11. Ehrnhoefer DE, Bieschke J, Boeddrich A et al (2008) EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 15:558–566

    Article  CAS  PubMed  Google Scholar 

  12. Hauber I, Hohenberg H, Holstermann B et al (2009) The main green tea polyphenol epigallocatechin-3-gallate counteracts semen-mediated enhancement of HIV infection. Proc Natl Acad Sci USA 106:9033–9038

    Article  CAS  PubMed  Google Scholar 

  13. Mereles D, Wanker EE, Katus HA (2008) Therapy effects of green tea in a patient with systemic light-chain amyloidosis. Clin Res Cardiol 97:341–344

    Article  PubMed  Google Scholar 

  14. Lang RM, Bierig M, Devereux RB et al (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440–1463

    Article  PubMed  Google Scholar 

  15. Nagueh SF, Appleton CP, Gillebert TC et al (2009) Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 22:107–133

    Article  PubMed  Google Scholar 

  16. Yock PG, Popp RL (1984) Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 70:657–662

    CAS  PubMed  Google Scholar 

  17. Ommen SR, Nishimura RA, Hurrel DG et al (2000) Assessment of right atrial pressure with 2-dimensional and Doppler-echocardiography: a simultaneous catheterization and echocardiography study. Mayo Clin Proc 75:24–29

    Article  CAS  PubMed  Google Scholar 

  18. Levy D, Anderson KM, Savage DD et al (1988) Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 108:7–13

    CAS  PubMed  Google Scholar 

  19. Siqueira-Filho AG, Cunha CL, Tajik AJ et al (1981) M-mode and two-dimensional echocardiographic features in cardiac amyloidosis. Circulation 63:188–196

    CAS  PubMed  Google Scholar 

  20. Hongo M, Ikeda S (1986) Echocardiographic assessment of the evolution of amyloid heart disease: a study with familial amyloid polyneuropathy. Circulation 73:249–256

    CAS  PubMed  Google Scholar 

  21. Klein AL, Hatle LK, Burstow DJ et al (1990) Comprehensive Doppler assessment of right ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 15:99–108

    Article  CAS  PubMed  Google Scholar 

  22. Klein AL, Hatle LK, Taliercio CP et al (1990) Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 16:1135–1141

    Article  CAS  PubMed  Google Scholar 

  23. Bellavia D, Pellikka PA, Abraham TP et al (2008) Evidence of impaired left ventricular systolic function by Doppler myocardial imaging in patients with systemic amyloidosis and no evidence of cardiac involvement by standard two-dimensional and Doppler echocardiography. Am J Cardiol 101:1039–1045

    Article  PubMed  Google Scholar 

  24. Palladini G, Lavatelli F, Russo P et al (2006) Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 107:3854–3858

    Article  CAS  PubMed  Google Scholar 

  25. Jantunen E, Itälä M, Lehtinen T et al (2006) Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1,482 transplanted patients. Eur J Haematol 76:245–250

    Article  CAS  PubMed  Google Scholar 

  26. Robertson IM, Li MX, Sykes BD (2009) The solution structure of human cardiac troponin C in complex with the green tea polyphenol; (−)-epigallocatechin-3-gallate. J Biol Chem 284:23012–23023

    Article  CAS  PubMed  Google Scholar 

  27. Liao R, Jain M, Teller P et al (2001) Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 104:1594–1597

    CAS  PubMed  Google Scholar 

  28. Sheng R, Gu ZL, Xie ML et al (2009) EGCG inhibits proliferation of cardiac fibroblasts in rats with cardiac hypertrophy. Planta Med 75:113–120

    Article  CAS  PubMed  Google Scholar 

  29. Grünig E, Janssen B, Mereles D et al (2000) Abnormal pulmonary artery pressure response in asymptomatic carriers of primary pulmonary hypertension gene. Circulation 102:1145–1150

    PubMed  Google Scholar 

  30. Henning SM, Niu Y, Liu Y et al (2005) Bioavailability and antioxidant effect of epigallocatechin gallate administered in purified form versus as green tea extract in healthy individuals. J Nutr Biochem 16:610–616

    Article  CAS  PubMed  Google Scholar 

  31. Chow HH, Hakim IA, Vining DR et al (2005) Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Clin Cancer Res 11:4627–4633

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Derliz Mereles.

Additional information

D. Mereles and S. J. Buss contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mereles, D., Buss, S.J., Hardt, S.E. et al. Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis. Clin Res Cardiol 99, 483–490 (2010). https://doi.org/10.1007/s00392-010-0142-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-010-0142-x

Keywords

Navigation